Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. It also offers other pharmaceutical products under the Letairis, Ranexa, AmBisome, and Zydelig brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:GILD
CUSIP37555810
Phone650-574-3000
Debt
Debt-to-Equity Ratio1.32
Current Ratio2.84
Quick Ratio2.75
Price-To-Earnings
Trailing P/E Ratio10.04
Forward P/E Ratio13.41
P/E Growth-6.7
Sales & Book Value
Annual Sales$26.11 billion
Price / Sales3.85
Cash Flow$9.6244 per share
Price / Cash8.04
Book Value$15.69 per share
Price / Book4.93
Profitability
EPS (Most Recent Fiscal Year)$8.56
Net Income$4.63 billion
Net Margins14.03%
Return on Equity45.49%
Return on Assets15.63%
Miscellaneous
Employees10,000
Outstanding Shares1,300,260,000
Market Cap$100,614.20
Gilead Sciences (NASDAQ:GILD) Frequently Asked Questions
What is Gilead Sciences' stock symbol?
Gilead Sciences trades on the NASDAQ under the ticker symbol "GILD."
How often does Gilead Sciences pay dividends? What is the dividend yield for Gilead Sciences?
Gilead Sciences declared a quarterly dividend on Tuesday, May 1st. Investors of record on Friday, June 15th will be paid a dividend of $0.57 per share on Thursday, June 28th. This represents a $2.28 dividend on an annualized basis and a yield of 2.95%. The ex-dividend date is Thursday, June 14th. View Gilead Sciences' Dividend History.
How were Gilead Sciences' earnings last quarter?
Gilead Sciences, Inc. (NASDAQ:GILD) issued its earnings results on Tuesday, May, 1st. The biopharmaceutical company reported $1.48 EPS for the quarter, missing the Thomson Reuters' consensus estimate of $1.67 by $0.19. The biopharmaceutical company earned $5.09 billion during the quarter, compared to analyst estimates of $5.40 billion. Gilead Sciences had a return on equity of 45.49% and a net margin of 14.03%. The business's quarterly revenue was down 21.8% compared to the same quarter last year. During the same period last year, the business posted $2.23 EPS. View Gilead Sciences' Earnings History.
When is Gilead Sciences' next earnings date?
What price target have analysts set for GILD?
25 equities research analysts have issued 12 month price targets for Gilead Sciences' shares. Their forecasts range from $72.00 to $105.00. On average, they anticipate Gilead Sciences' share price to reach $88.2271 in the next twelve months. This suggests a possible upside of 14.0% from the stock's current price. View Analyst Ratings for Gilead Sciences.
What is the consensus analysts' recommendation for Gilead Sciences?
25 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gilead Sciences in the last year. There are currently 9 hold ratings, 15 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy."
What are Wall Street analysts saying about Gilead Sciences stock?
Here are some recent quotes from research analysts about Gilead Sciences stock:
- 1. According to Zacks Investment Research, "Gilead’s first-quarter results were disappointing with both earnings and sales missing estimates as the magnitude of the decline in HCV sales was wider-than-expected due to lower patient starts and increasing competition. Nevertheless, Gilead is now banking on its HIV franchise and newer avenues like the CAR-T therapy to drive growth. The HIV franchise maintains momentum driven by the rapid adoption of Descovy-based regimens. The FDA approval of Biktarvy has further widened the portfolio. The CHMP has also adopted a positive opinion on the regimen and a tentative approval is expected in the third-quarter. The initial uptake of Yescarta is encouraging. Meanwhile, Gilead is intending to foray into the NASH market with selonsertib and filgotinib. Both the candidates are being evaluated in late stage studies and a tentative approval will diversify Gilead’s portfolio.Shares have performed better than the industry in the last twelve months." (5/7/2018)
- 2. Needham & Company LLC analysts commented, "Gilead reported $5.09B 1Q18 total revenue, below our $5.52B and consensus $5.3B ests. Product sales were $5.00B, below our $5.41B est. Gilead continues to lose share to Abbvie in HCV. Trend is worrisome, although mgmt still guiding for market share stabilization mid-2018. HIV sales in 1Q18 also disappointed, reportedly driven by bigger than expected seasonal inventory draw-down and generic TDF. Growth in HIV (i.e. Biktarvy success) is critical. NASH program has not yet distinguished itself, awaiting data from selonsertib Phase 3 trials (1H19) and 48wk combination Phase 2 trials (2020). Yescarta and cell therapy programs are in early stages." (5/2/2018)
- 3. Leerink Swann analysts commented, "RARE’s 4Q report this afternoon was relatively in line with expectations. Incremental clinical updates for burosumab in young children and in adults with osteomalacia (bone softening) in the report further support the drug’s utility in both populations. The year ahead is shaping up to be catalyst-rich for RARE, with data from two gene therapy programs, the Phase 3 of trihep in Glut1 DS, and a decision on trihep registration plans in FAOD expected over the coming months. Although we continue to expect a slow rollout of burosumab (PDUFA date 4/17/18) and Mepsevii, we see opportunity for further upside in shares over the course of 2018. Maintain OW." (2/22/2018)
- 4. BMO Capital Markets analysts commented, "Early biopotency signals from a single patient dosed with ABO-101 (for Sanfilippo B), demonstrate targeted reduction on toxic sugars." (2/7/2018)
- 5. Maxim Group analysts commented, "We returned from Beijing, China and listened as Tim Moore, EVP of Technical Operations and the CEO of Fosun Kite Biotechnology co. (Richard Wang) presented manufacturing plans for the launch of Yescarta, and the opportunity in China (see the slides in the pages that follow). Suffice to say, we were impressed and left clear with the notion that Gilead (and Kite) can overcome manufacturing challenges to commercialize in the U.S. and globally, especially China, this new innovative therapy. As a result, we are upgrading Gilead to Buy, from Hold and establishing a $94 price target." (11/30/2017)
Are investors shorting Gilead Sciences?
Gilead Sciences saw a decrease in short interest during the month of June. As of June 29th, there was short interest totalling 13,703,362 shares, a decrease of 16.0% from the June 15th total of 16,306,232 shares. Based on an average daily volume of 6,622,004 shares, the short-interest ratio is presently 2.1 days. Approximately 1.1% of the company's shares are sold short. View Gilead Sciences' Current Options Chain.
Who are some of Gilead Sciences' key competitors?
Some companies that are related to Gilead Sciences include Amgen (AMGN), Biogen (BIIB), NOVOZYMES A/S/S (NVZMY), Seattle Genetics (SGEN), Neurocrine Biosciences (NBIX), bluebird bio (BLUE), Qiagen (QGEN), AveXis (AVXS), BIO-TECHNE (TECH), Ablynx (ABLYF), China Biologic Products (CBPO), Spark Therapeutics (ONCE), Crispr Therapeutics (CRSP), Aerie Pharmaceuticals (AERI) and argenx (ARGX).
Who are Gilead Sciences' key executives?
Gilead Sciences' management team includes the folowing people:
- John F. Milligan, President, Chief Executive Officer & Director
- Robin L. Washington, CFO, Principal Accounting Officer & Executive VP
- Andrew Cheng, Chief Medical Officer & Executive Vice President
- John G. McHutchison, Chief Scientific Officer
- Brett A. Pletcher, Secretary, Chief Compliance Officer & Executive VP
Has Gilead Sciences been receiving favorable news coverage?
News stories about GILD stock have been trending somewhat positive on Sunday, according to Accern. The research group ranks the sentiment of media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Gilead Sciences earned a daily sentiment score of 0.07 on Accern's scale. They also gave news articles about the biopharmaceutical company an impact score of 47.53 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next several days.
Who are Gilead Sciences' major shareholders?
Gilead Sciences' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Swedbank (0.15%), Confluence Investment Management LLC (0.09%), NN Investment Partners Holdings N.V. (0.07%), Gateway Investment Advisers LLC (0.06%), Fisher Asset Management LLC (0.04%) and Gulf International Bank UK Ltd (0.03%). Company insiders that own Gilead Sciences stock include Gayle E Wilson, Gregg H Alton, James R Meyers, John C Martin, John F Milligan, John Francis Cogan, John W Madigan, Kevin E Lofton, Paul Rutherford Carter and Robin L Washington. View Institutional Ownership Trends for Gilead Sciences.
Which institutional investors are selling Gilead Sciences stock?
GILD stock was sold by a variety of institutional investors in the last quarter, including JLB & Associates Inc., Atria Investments LLC, New England Research & Management Inc., Swedbank, Empirical Finance LLC, American National Bank, Addenda Capital Inc. and Bremer Trust National Association. Company insiders that have sold Gilead Sciences company stock in the last year include Gayle E Wilson, Gregg H Alton, James R Meyers, John C Martin, John F Milligan, John Francis Cogan and Robin L Washington. View Insider Buying and Selling for Gilead Sciences.
Which institutional investors are buying Gilead Sciences stock?
GILD stock was purchased by a variety of institutional investors in the last quarter, including Confluence Investment Management LLC, Addenda Capital Inc., State of Alaska Department of Revenue, Fisher Asset Management LLC, Manning & Napier Group LLC, IFM Investors Pty Ltd, NN Investment Partners Holdings N.V. and First National Bank of Mount Dora Trust Investment Services. View Insider Buying and Selling for Gilead Sciences.
How do I buy shares of Gilead Sciences?
Shares of GILD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Gilead Sciences' stock price today?
One share of GILD stock can currently be purchased for approximately $77.38.
How big of a company is Gilead Sciences?
Gilead Sciences has a market capitalization of $100.61 billion and generates $26.11 billion in revenue each year. The biopharmaceutical company earns $4.63 billion in net income (profit) each year or $8.56 on an earnings per share basis. Gilead Sciences employs 10,000 workers across the globe.
How can I contact Gilead Sciences?
Gilead Sciences' mailing address is 333 LAKESIDE DRIVE, FOSTER CITY CA, 94404. The biopharmaceutical company can be reached via phone at 650-574-3000 or via email at [email protected]
MarketBeat Community Rating for Gilead Sciences (NASDAQ GILD)
MarketBeat's community ratings are surveys of what our community members think about Gilead Sciences and other stocks. Vote "Outperform" if you believe GILD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GILD will underperform the S&P 500 over the long term. You may vote once every thirty days.
